Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark
Stocks in this Quantisnow insightHealth Care
Historical context for DNA
Across the 11 sessions after earlier DNA headlines, the stock closed higher 9 times and lower 2 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DNA | SPY |
|---|---|---|---|
| Jan 13, 2026 | Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference | +0.6% | -0.2% |
| Dec 22, 2025 | Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach | +8.5% | +0.6% |
| Dec 17, 2025 | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | -0.2% | -1.1% |
| Dec 11, 2025 | ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies | +1.2% | +0.2% |
| Dec 9, 2025 | Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety | +1.7% | -0.1% |
| Dec 5, 2025 | Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC | +0.4% | +0.2% |
Quantisnow market dataNYSE
DNA
Ginkgo Bioworks Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for DNA
Full DNA profile on Quantisnow Follow DNA and get a push notification the moment its next story breaks.